{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:17:50Z","timestamp":1791562670523,"version":"4.3.4"},"reference-count":33,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004834","name":"Jaume I University","doi-asserted-by":"publisher","award":["(UJI-2021-71); SomUJIContraCovid (crowdfunding campaign)"],"award-info":[{"award-number":["(UJI-2021-71); SomUJIContraCovid (crowdfunding campaign)"]}],"id":[{"id":"10.13039\/501100004834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Since the outbreak of COVID-19, one of the strategies used to search for new drugs has been to find inhibitors of the main protease (Mpro) of the virus SARS-CoV-2. Initially, previously reported inhibitors of related proteases such as the main proteases of SARS-CoV and MERS-CoV were tested. A huge effort was then carried out by the scientific community to design, synthesize and test new small molecules acting as inactivators of SARS-CoV-2 Mpro. From the chemical structure view, these compounds can be classified into two main groups: one corresponds to modified peptides displaying an adequate sequence for high affinity and a reactive warhead; and the second is a diverse group including chemical compounds that do not have a peptide framework. Although a drug including a SARS-CoV-2 main protease inhibitor has already been commercialized, denoting the importance of this field, more compounds have been demonstrated to be promising potent inhibitors as potential antiviral drugs.<\/jats:p>","DOI":"10.3390\/molecules27082523","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T01:03:01Z","timestamp":1650330181000},"page":"2523","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":59,"title":["Advances in the Development of SARS-CoV-2 Mpro Inhibitors"],"prefix":"10.3390","volume":"27","author":[{"given":"Laura","family":"Agost-Beltr\u00e1n","sequence":"first","affiliation":[{"name":"Departament de Qu\u00edmica Inorg\u00e0nica i Org\u00e0nica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"de la Hoz-Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Departament de Qu\u00edmica Inorg\u00e0nica i Org\u00e0nica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lled\u00f3","family":"Bou-Iserte","sequence":"additional","affiliation":[{"name":"Departament de Qu\u00edmica Inorg\u00e0nica i Org\u00e0nica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Departament de Qu\u00edmica Inorg\u00e0nica i Org\u00e0nica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adri\u00e1n","family":"Fern\u00e1ndez-de-la-Pradilla","sequence":"additional","affiliation":[{"name":"Departament de Qu\u00edmica F\u00edsica i Anal\u00edtica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-734X","authenticated-orcid":false,"given":"Florenci V.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Departament de Qu\u00edmica Inorg\u00e0nica i Org\u00e0nica, Universitat Jaume I, 12080 Castell\u00f3, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022, March 22). WHO Coronavirus Disease (COVID-19) Dashboard. Available online: https:\/\/covid19.who.int\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/cbic.202000047","article-title":"Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV","volume":"21","author":"Morse","year":"2020","journal-title":"ChemBioChem"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","article-title":"VMD: Visual Molecular Dynamics","volume":"14","author":"Humphrey","year":"1996","journal-title":"J. Mol. Graph."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"9609","DOI":"10.1038\/s41598-021-89013-w","article-title":"Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model","volume":"11","author":"Carnaccini","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 M pro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Boras, B., Jones, R.M., Anson, B.J., Arenson, D., Aschenbrenner, L., Bakowski, M.A., Beutler, N., Binder, J., Chen, E., and Eng, H. (2020). Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19. BioRxiv.","DOI":"10.1101\/2020.09.12.293498"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"105455","DOI":"10.1016\/j.bioorg.2021.105455","article-title":"The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus","volume":"117","author":"Qiao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"W\u0119glarz-Tomczak, E., Tomczak, J.M., Talma, M., and Brul, S. (2020). Ebselen as a highly active inhibitor of PLProCoV2. BioRxiv.","DOI":"10.1101\/2020.05.17.100768"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"eabd0345","DOI":"10.1126\/sciadv.abd0345","article-title":"Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease","volume":"6","author":"Alvarado","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1038\/s41467-021-23313-7","article-title":"Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives","volume":"12","author":"Amporndanai","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Madabeni, A., Nogara, P.A., Omage, F.B., Teixeida Rocha, J.B., and Orian, L. (2021). Mechanistic Insight into SARS-CoV-2 Mpro Inhibition by Organoselenides: The Ebselen Case Study. Appl. Sci., 11.","DOI":"10.3390\/app11146291"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104889","DOI":"10.1016\/j.bioorg.2021.104889","article-title":"Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals","volume":"112","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1021\/acsptsci.0c00130","article-title":"Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors","volume":"3","author":"Ma","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/jacs.1c08402","article-title":"Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses","volume":"147","author":"Luttens","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1038\/s41598-022-06306-4","article-title":"Non-covalent SARS-CoV-2 Mpro inhibitors developed from in silico screen hits","volume":"12","author":"Rossetti","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","article-title":"A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication","volume":"12","author":"Hattori","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","article-title":"Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure\u2013Activity Relationship, and X-ray Structural Studies","volume":"64","author":"Ghosh","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alhadrami, H.A., Burgio, G., Thissera, B., Orfali, R., Jiffri, S.E., Yaseen, M., Sayed, A.M., and Rateb, M.E. (2022). Neoechinulin A as a Promising SARS-CoV-2 Mpro Inhibitor: In Vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors. Mar. Drugs, 20.","DOI":"10.3390\/md20030163"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbrc.2020.12.106","article-title":"The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease","volume":"591","author":"Chiou","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e01253-21","DOI":"10.1128\/JVI.01253-21","article-title":"Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus","volume":"96","author":"Zhang","year":"2022","journal-title":"J. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"114030","DOI":"10.1016\/j.ejmech.2021.114030","article-title":"Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CLpro inhibitors for treating COVID-19","volume":"228","author":"Zhang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"114046","DOI":"10.1016\/j.ejmech.2021.114046","article-title":"Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors","volume":"229","author":"Stille","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10716","DOI":"10.1002\/anie.202016768","article-title":"Re1 Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease","volume":"60","author":"Karges","year":"2021","journal-title":"Angew. Chem. Int. Ed."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"10083","DOI":"10.1039\/D1CC03563K","article-title":"Zinc2+ ion inhibits SARS-CoV-2 main protease and viral replication in vitro","volume":"57","author":"Panchariya","year":"2021","journal-title":"Chem. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12226","DOI":"10.1039\/D1DT02499J","article-title":"Zinc thiotropolone combinations as inhibitors of the SARS-CoV-2 main protease","volume":"50","author":"DeLaney","year":"2021","journal-title":"Dalton Trans."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1039\/D1SC04515F","article-title":"Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy","volume":"13","author":"Wang","year":"2022","journal-title":"Chem. Sci."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2523\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:53:49Z","timestamp":1760136829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/8\/2523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["molecules27082523"],"URL":"https:\/\/doi.org\/10.3390\/molecules27082523","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202204.0065.v1","asserted-by":"object"}]},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}